{
    "organizations": [],
    "uuid": "bc4c0df15f0a2059b19e6fcdcc140d661fd3e9c2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pfizer-says-us-eu-and-japan-health/brief-pfizer-says-u-s-eu-and-japan-health-authorities-accept-lorlatinib-for-review-idUSFWN1Q20U1",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer says U.S., EU And Japan Health Authorities Accept Lorlatinib For Review",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - Pfizer Inc:\n* U.S., EU AND JAPAN HEALTH AUTHORITIES ACCEPT REGULATORY SUBMISSIONS FOR REVIEW OF PFIZERâ€™S THIRD-GENERATION ALK INHIBITOR LORLATINIB\n* PFIZER INC - U.S. NEW DRUG APPLICATION FOR LORLATINIB GRANTED FDA PRIORITY REVIEW Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-12T21:07:00.000+02:00",
    "crawled": "2018-02-13T15:52:39.045+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "pfizer",
        "inc",
        "eu",
        "japan",
        "health",
        "authority",
        "accept",
        "regulatory",
        "submission",
        "review",
        "pfizer",
        "alk",
        "inhibitor",
        "lorlatinib",
        "pfizer",
        "inc",
        "new",
        "drug",
        "application",
        "lorlatinib",
        "granted",
        "fda",
        "priority",
        "review",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}